STADA

Overview

Overview

STADA is a publicly traded, international
company with a focus on the healthcare market.

STADA Business Model

  • Focus on products with off-patent active pharmaceutical ingredients in the health care and pharmaceutical market
  • Segments

    • Generics (59% share in adjusted Group sales)
    • Branded Products (41% share in adjusted Group sales)

    • Strategic success factors

      • Orientation on long-term growth markets
      • Comprehensive portfolio of generics including selected biosimilars
      • Attractive-margin branded product portfolio with increased internationalization of successful brands
      • Strong product development including well-filled pipeline
      • Global sales structure with further internationalization potential
      • A focused acquisition policy
      • A functional organizational structure with close-to-market sales companies
      • Continuous cost optimization and efficient cost management
      • Excellent and committed employees

    STADA Financial Year 2016

    • Reported Group sales increase by 1% to € 2.14 billion – Group sales adjusted for currency and portfolio effects increase by 3% to € 2.17 billion
    • Adjusted sales in the Generics segment increase by 3% to € 1,287.4 million
    • Adjusted sales in the Branded Products segment record growth of 4% to € 879.8 million – further expansion of the self-pay portfolio
    • Reported key earnings figures

      • Reported EBITDA records a decrease of 4% to € 361.5 million
      • Reported net income decreases by 22% to € 85.9 million

    • Adjusted key earnings figures

      • Adjusted EBITDA shows an increase of 2% to € 398.0 million
      • Adjusted net income grows by 7% to € 177.3 million

    • Strategic further development with numerous initiatives introduced to improve performance
    • Fundamental change to reporting structures carried out – management by operating segments
    • Successful product development with a total of 665 product launches
    • Selected value-enhancing acquisitions to strengthen the Branded Products and Generics segments
    • Significant growth in the STADA share price of 32%
    • Proposal to increase the dividend by 3% to € 0.72 per STADA share

    STADA Outlook

    • Guidance for 2017

      • Group sales adjusted for currency and portfolio effects between € 2.280 billion and € 2.350 billion
      • Adjusted EBITDA between € 430 million and € 450 million
      • Adjusted net income between € 195 million and € 205 million
      • Ratio of net debt, excluding further acquisitions, to adjusted EBITDA at a level of nearly 3

    • Strategic outlook for 2019

      • Adjusted Group sales between € 2.650 billion and € 2.700 billion
      • Adjusted EBITDA between € 570 million and € 590 million
      • Adjusted net income between € 250 million and € 270 million

     

     

    Quality at STADA

    Quality at STADA

    Quality and responsibility to all who use our products or services is a fundamental part of our corporate strategy.

    Learn more

    Career at STADA

    Career at STADA

    STADA's employees, with their extensive expertise, their experience and their strong commitment, play an important part in the longstanding success of the Group.

    Learn more

    Media Relations

    Media Relations

    In addition to press releases on current issues Journalists can find background information on areas such as personnel, organizational structure, products and manufacturing.

    Learn more

    Career at STADA

    Career at STADA

    STADA's employees, with their extensive expertise, their experience and their strong commitment, play an important part in the longstanding success of the Group.

    Learn more

    Investor Relations

    Investor Relations

    Here you can find all the facts and background information about the STADA securities.

    Lern more

    Sustainability

    Sustainability

    For STADA "All the best" means taking responsibility.

    Learn more

    entdecken